Table 2.
Clinical trials reporting uncertain benefit of stem cells transplantation after acute myocardial infarction
| Author | Year | Reference | Trials | Cells source | N. patients | Mean % LVEF variation |
|---|---|---|---|---|---|---|
| Fuchs S | 2003 | [9] | – | BMC | 10 | = |
| Tse HF | 2003 | [6] | – | BMC | 8 | = |
| Janssens S | 2006 | [20] | – | BMC | 67 | < 1 |
| Lunde K | 2006 | [29] | ASTAMI | BMC | 50 | > 0.6 |
| Lunde K | 2007 | [30] | ASTAMI | BMC | 100 | = |
| Hirsch A | 2008 | [25] | HEBE | BMC | 200 | = |
| Tendera M | 2009 | [26] | REGENT | BMC | 200 | = |
| Gyongyosi | 2009 | [27] | MYSTAR | BMC | 60 | = |
| Surder D | 2010 | [28] | SWISS-AMI | BMC | 192 | = |
| Traverse JH | 2012 | [34] | TIME | BMC | 120 | = |
| Wollert KC | 2017 | [24] | BOOST-2 | BMC | 153 | < 1 |
| Fernandez-Avilés F | 2018 | [31] | CAREMI | Cardiac stem cells | 49 | = |
| Nicolau JC | 2018 | [32] | MiHeart/AMI | BMC | 121 | = |
| Mathur A | 2020 | [33] | BAMI | BMC | 375 | = |
| Total | 1705 |
BMC bone marrow-derived cells